Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	4.95B +33.8%
Revenue (ttm)	930.06M -25.5%
Net Income	407.47M -1.6%
EPS	0.53 -1.9%
Shares Out	n/a
PE Ratio	12.15
Forward PE	n/a
Dividend	0.67 (21.28%)
Ex-Dividend Date	Jan 30, 2026

Volume	167,800
Open	3.030
Previous Close	3.050
Day's Range	3.030 - 3.200
52-Week Range	2.370 - 3.750
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 3,890
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2025, SGX:T14's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial numbers in CNY